Findings

What do systematic reviews say?

4 questions · 4 findings · 2 reviews · Infectious Diseases

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 2 · 50%Very low 0 · 0%Low 2 · 50%Moderate 0 · 0%High 0 · 0%

Primaquine five days vs 14 days

Serious adverse events · People with P. vivax malaria1

1 finding from 1 review

Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 186 participants
GRADE not reported

Primaquine three days vs 14 days

Serious adverse events · People with P. vivax malaria1

1 finding from 1 review

Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 262 participants
GRADE not reported

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

Serious adverse events (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events (42 days) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 1 [0.25, 3.97]
1 study · 1271 participants
Low

Pyronaridine‐artesunate (PY‐AS) vs artemether‐lumefantrine (AL)

Serious adverse events (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events (42 days) compared with artemether‐lumefantrine (AL) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 1.16 [0.3, 4.5]
3 studies · 2004 participants
Low